However, the inhibitory potency of CRID3 is diminished by disease-associated mutations in and around the NLRP3 NACHT in preclinical mouse models of CAPS and in LPS-stimulated PBMCs of CAPS patients (Vande Walle et al, 2019; Weber et al, 2022; Vande Walle & Lamkanfi, 2023). The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.